Global Point of Care

Results on your schedule. Answers in your hands.

Respiratory infections are contagious, so quick results are important.

Easier access. Faster results. That’s the power of rapid testing.

There’s rarely a convenient time to take a medical test. The good news is, you no longer need to go out of your way to get fast, simple, and more accessible testing. From corner pharmacies to local urgent care clinics, our rapid test products are widely available. The same testing technology that is used in doctor's offices & emergency rooms is now also available in convenient care locations. Rapid tests are essential tools in helping to reduce the spread because they quickly identify respiratory infections.

Available Products
ID NOW

ID NOW™ Rapid Molecular Testing

Used widely by urgent care clinics, pharmacies, doctor's offices, and hospitals, ID NOW is a fast, convenient, and proven way to test for respiratory infections.

This rapid molecular instrument provides your healthcare professional with timely results, that inform your treatment, which may include antivirals or antibiotics, so you can get well sooner. Available tests include:

  • Influenza (Flu)
  • Strep A
  • COVID-19
  • RSV
BinaxNOW COVID-19 Antigen Self-Test

BinaxNOW™ COVID-19 Antigen Self Test

Discover the fast, proven and trusted COVID-19 antigen test that is readily available over-the-counter at retailers and pharmacies across the country. BinaxNOW™ COVID-19 Antigen Self Test is a simple solution for COVID-19 infection detection. Detects multiple strains, including Delta and Omicron variants.*

Quick results for personal use to have peace of mind (self reporting only - does not provide a verified result)

Find out more about rapid molecular testing with our Patient Learning Series (PALS)

When you or someone you care about is sick and you seek treatment, a test is often used to figure out what is going in inside of you. Learn about respiratory illnesses and the newer advanced test technology that offers faster time to test results. Knowing now means you’ll be treated earlier which can help you get well sooner. Download our PALS information for more information. 

Find out what your symptoms are saying

Find out more about how rapid molecular testing works with our Patient Learning Series (PALS). 

Find Tests Near You

This search tool will help you find the test you need at the location you prefer. To get started, find a healthcare provider offering ID NOW rapid molecular testing.

Healthcare Professionals

To be added to our ID NOW Healthcare Professional locator tool, please provide the required information for each location you would like to be included on the locator tool.

*Abbott conducted a computational analysis of the detection of multiple SARS-COV-2 Strains, including the Delta and Omicron variants, and predicts no impact to the performance of our BinaxNOW™ COVID-19 Antigen Self Test.

The BinaxNOW™ COVID-19 Antigen Self Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb 3(b)(1), unless the declaration is terminated or authorization is revoked soon. For serial testing, the BinaxNOW COVID-19 Antigen Self-Test should be performed twice in 3 days, at least 24 hours (and no more than 48 hours) apart. For symptomatic use, a single test can be used.

The ID NOW™ COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.